Drug Trial Radar · NCT03981523
New Therapies and Biomarkers for Chagas Infection
Last checked: Nov 20, 2026Latest source record: Jul 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
450
Actual
Start
Dec 18, 2019
Primary completion
May 29, 2024
Study completion May 31, 2024
Sponsor
- Lead sponsor
- University of Texas, El PasoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Fundación Ciencia y Estudios Aplicados para el Desarrollo en Salud y Medio Ambiente (CEADES); Barcelona Institute for Global Health; Institute of Parasitology and Biomedicine Lopez Neyra; Food and Drug Administration (FDA); Drugs for Neglected Diseases; Mundo Sano Foundation; National Institute of Allergy and Infectious Diseases (NIAID)
- First posted
- Jun 11, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Chagas disease (CD) is an endemic zoonotic disease with a significant global impact. Current approved treatments for CD (benznidazole (BZN) and nifurtimox (NFX)) were developed in the 1970s with regimens and dosing intervals derived from decades-old patient series and with very limited direct comparisons. Treatment recommendations vary significantly from country to country and the comparative evidence-base with the current treatment regimens is limited. The reported efficacy of both drugs in patients with T. cruzi infection is variable and depends on the disease stage, the drug dose, the age of patients, and the infecting T. cruzi strain or genotype. Due to a therapeutic failure of at least 20% after 12 months in chronic patients and the high rate of adverse events, together with the recent data that suggest that we may be overdosing patients, we propose to test new dosing regimens of these two old compounds. Hypotheses: * Lowering the frequency of drug dosing of BZN and NFX, the plasma drug levels of the drugs within the therapeutic range will be maintained. * The duration of treatment with BZN or NFX may be related to the effectiveness of these drugs. * Blood levels of the proposed biomarkers will significantly diminish or became negative after a relatively short interval after treatment.
Conditions
- Trypanosoma Cruzi Infection
- Chagas Disease
Interventions
BenznidazoleDrug
50 mg and 100 mg tablet taken orally
NifurtimoxDrug
120 mg tablet taken orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sustained Parasitological Clearance by qPCR at End of Follow-Up (36 months)Time frame: up to 36 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Platform for the Comprehensive Care of Patients with Chagas Disease
Sucre, Bolivia
Platform for the Comprehensive Care of Patients with Chagas Disease
Cochabamba, Cercado, Bolivia
Platform for the Comprehensive Care of Patients with Chagas Disease
Tarija, Cercado, Bolivia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.